헬릭스미스
Financials
Valuation Metrics
헬릭스미스's Market Cap is ₩1530B. At end of 2025 it was ₩2867B. Ranked #989 of 2,436 in KR market (top 41%), #484 of 1,649 on KOSDAQ (top 29%), #114 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 49%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 153.03B KRW | KR#989/2,436 Sec#114/234 |
| Revenue | 2.22B KRW | KR#2,386/2,436 Sec#215/234 |
| Net Income | -330.8M KRW | KR—/2,436 Sec—/234 |
| Total Assets | 141.94B KRW | KR#1,508/2,436 Sec#121/234 |
| Net Assets | 140.28B KRW | KR#1,153/2,436 Sec#87/234 |
| Employees | 44 | KR#2,074/2,436 Sec#187/234 |
| Value | ||
| P/B | 1.09x | KR#1,553/2,436 Sec#103/234 |
| P/S | 68.85x | KR#2,377/2,436 Sec#202/234 |
| FCF Yield | -4.65% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -0.24% | KR#1,506/2,436 Sec#104/234 |
| ROA | -0.23% | KR#1,516/2,436 Sec#105/234 |
| Op. Margin | -415.62% | KR#2,369/2,436 Sec#203/234 |
| Revenue Growth | -40.36% | KR#2,241/2,436 Sec#200/234 |
| Financial Health | ||
| Debt Ratio | 101.19% | KR#329/2,436 Sec#43/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | -7.11B KRW | KR#1,602/2,436 Sec#133/234 |
| Cash | 31.08B KRW | KR#986/2,436 Sec#64/234 |
| Current Ratio | 107.85x | KR#2/2,436 Sec#2/234 |
| Performance | ||
| 1Y Return | -1.19% | KR#785/2,436 Sec#55/234 |
| 1M Return | -17.31% | KR#2,118/2,436 Sec#201/234 |
| From 52W High | -66.67% | KR#2,022/2,436 Sec#171/234 |
| 1Y MDD | -70.38% | KR#1,966/2,436 Sec#170/234 |
| Trading | ||
| Volume | 133,631 shares | KR#687/2,436 Sec#65/234 |
| Foreign Own. | 4.17% | KR#878/2,436 Sec#84/234 |
| Per Share | ||
| EPS | -7 KRW | KR—/2,436 Sec—/234 |
| BPS | 3,056 KRW | KR#1,800/2,436 Sec#140/234 |
Company Info
Established in 1996, this R&D company was listed on KOSDAQ in 2005. It possesses global biotech-level resources and capabilities spanning from candidate substance discovery to preclinical trials, analysis, and production. The company provides diverse platform-based services, leveraging its experience with US FDA Orphan Drug, Fast Track, and RMAT designations. Building on its new material development expertise, it conducts B2B businesses for health functional foods and premium cosmetics. Helixmith is headquartered in Gangseo-gu, Seoul.